Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

SpaceX Is A 'Money Furnace,' Former Hedge Fund Manager Says As Filing Reveals $4.3 Billion Quarterly Loss

View original at finance.yahoo.com
SpaceX Is A 'Money Furnace,' Former Hedge Fund Manager Says As Filing Reveals $4.3 Billion Quarterly Loss Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SpaceX is a 'money furnace'

    60% confidence

  • Anthropic has agreed to pay SpaceX approximately $1.25 billion a month to rent capacity at its Colossus data centers through 2029

    60% confidence

  • SpaceX's plans for solar-powered data centers in orbit make it look more like a science experiment than a business

    60% confidence

  • SpaceX plans to build solar-powered data centers in orbit to sidestep terrestrial power and cooling constraints

    60% confidence

  • SpaceX has lost approximately $37 billion since inception

    60% confidence

  • There is an 87% probability that SpaceX will deliver 2026's biggest IPO

    60% confidence

  • There is a 94% probability of SpaceX completing its stock market listing in June 2026

    60% confidence

  • SpaceX's valuation is the most extreme of any company imaginable, exceeding even Nvidia's despite Nvidia being hugely profitable with massive margins while SpaceX is not profitable

    60% confidence

Data points we hold from this source

Anthropic · data center monthly spend1.25 USD
SpaceX · ipo float percent5 percent
SpaceX · space division operating loss-662 USD
SpaceX · cumulative net loss-37 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com